



Biocon Limited
20th KM, Hosur Road
Electronic City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423

CIN : L24234KA1978PLC003417

www.biocon.com

BIO/SECL/EA/2025-26/162

January 14, 2026

To The Manager, BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code - 532523	To The Manager, National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050 Scrip Symbol - BIOCON
--	---

Dear Sir/ Madam,

Subject: Disclosure of the details of allotment in the Issue (as defined hereinafter) by Biocon Limited (the “Company”) in accordance with the Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements), 2015, as amended (“SEBI Listing Regulations”).

Re: Qualified Institutions Placement of equity shares of face value ₹ 5 each (“Equity Shares”) (such placement, the “Issue”) by the Company under Chapter VI of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (the “SEBI ICDR Regulations”) and Sections 23(1)(b), 42 and 62(1)(c) of the Companies Act, 2013, as amended.

In continuation of our earlier letters dated January 12, 2026 and January 14, 2026 on the captioned subject, we wish to inform you that, in respect of the Issue, the Fund Raising Committee (“Committee”) at its meeting held today, i.e., January 14, 2026, has *inter alia*, approved the issue and allotment of 11,26,64,585 Equity Shares of face value of ₹ 5 each to eligible qualified institutional buyers at the issue price of ₹ 368.35 per Equity Share (including a premium of Rs. 363.35 per Equity Share), aggregating to ₹ 41,500 million (Rupees Forty-One Thousand and Five Hundred million) pursuant to the Issue.

The Issue opened on January 12, 2026 and closed on January 14, 2026 and the same was intimated to you through our letters dated January 12, 2026 and January 14, 2026, respectively.

Pursuant to the allotment of Equity Shares in the Issue, the paid-up Equity Share capital of the Company stands increased from ₹ 7,54,12,15,940 consisting of 1,50,82,43,188 Equity Shares to ₹ 8,10,45,38,865 consisting of 1,62,09,07,773 Equity Shares of face value ₹ 5 each. The shareholding pattern of the Company before and after the Issue, will be submitted along with listing application in the format specified in Regulation 31 of the SEBI Listing Regulations.

Further, find attached herewith the list of allottees who have been allotted more than 5% of the Equity Shares offered in the Issue, marked as **Annexure 1**.

The information as required under Regulation 30 of the SEBI Listing Regulations read with Para A of Part - A of Schedule – III to the SEBI Listing Regulations and SEBI master circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, each as amended is as follows:



Type of securities issued and allotted (viz. equity shares, convertibles etc.)	Equity Shares
Type of Issuance (further public offering, rights issue, depository receipts (ADR/GDR), qualified institutions placement, preferential allotment etc.)	Qualified Institutions Placement
Total no. of securities issued	11,26,64,585 Equity Shares of face value ₹ 5 each at a price of ₹ 368.35 per Equity Share (including a premium of ₹ 363.35 per Equity Share)
Total amount for which the securities have been issued (approximately)	₹ 41,500 million

The meeting of the Committee commenced at 11:40 p.m. and concluded at 11:45 p.m.

Further, as informed vide our letter dated January 12, 2026, the trading window for dealing in securities of the Company for all insiders, as defined under the Code of Conduct for Prevention of Insider Trading of the Company which was already closed for the purpose of the Issue, shall open on January 17, 2026.

We request you to kindly take this on records, and the same be treated as compliance under the applicable regulations of the SEBI Listing Regulations.

Copy of this intimation is being also made available on the website of the Company at www.biocon.com.

Kindly take the same on record and acknowledge.

Thanking you

Yours faithfully

For Biocon Limited

Rajesh U. Shanoy
Company Secretary and Compliance Officer
ICSI membership number: A16328

Annexure 1

LIST OF ALLOTTEES WHO HAVE BEEN ALLOTTED MORE THAN 5% OF THE EQUITY SHARES OFFERED IN THE ISSUE

S. No.	Name of the Allottees	No. of Equity Shares Allotted	% of total Equity Shares offered in the Issue	Percentage (PAN Clubbed) (5 % and above)	Category
1.	SBI CONTRA FUND	11,266,460	10.0000	29.5181	MF
2.	SBI MULTICAP FUND	9,773,314	8.6747		
3.	SBI ELSS TAX SAVER FUND	4,072,215	3.6145		
4.	SBI FLEXICAP FUND	3,257,772	2.8916		
5.	SBI MIDCAP FUND	1,628,887	1.4458		
6.	SBI MULTI ASSET ALLOCATION FUND	1,628,887	1.4458		
7.	SBI MNC FUND	1,085,925	0.9639		
8.	SBI HEALTHCARE OPPORTUNITIES FUND	542,963	0.4819		
9.	ICICI PRUDENTIAL VALUE FUND	13,981,271	12.4096	29.5181	MF
10.	ICICI PRUDENTIAL PHARMA HEALTHCARE AND DIAGANOSTICS (P.H.D) FUND	10,587,759	9.3976		
11.	ICICI PRUDENTIAL INNOVATION FUND	3,257,772	2.8916		
12.	ICICI PRUDENTIAL EQUITY & DEBT FUND	2,714,810	2.4096		
13.	ICICI PRUDENTIAL MULTICAP FUND	1,221,665	1.0843		
14.	ICICI PRUDENTIAL MIDCAP FUND	950,184	0.8434		
15.	ICICI PRUDENTIAL ELSS TAX SAVER FUND	542,962	0.4819		
16.	MIRAE ASSET LARGE & MIDCAP FUND	3,807,987	3.3799		
17.	MIRAE ASSET LARGE CAP FUND	2,665,591	2.3660		
18.	MIRAE ASSET MIDCAP FUND	1,631,994	1.4485		
19.	MIRAE ASSET AGGRESSIVE HYBRID FUND	906,663	0.8047		
20.	MIRAE ASSET EQUITY SAVINGS FUND	90,666	0.0805		
21.	MIRAE ASSET BALANCED ADVANTAGE FUND	90,666	0.0805		
22.	MIRAE ASSET HEALTHCARE FUND	181,333	0.1609		
23.	MIRAE ASSET MULTI ASSET ALLOCATION FUND	126,932	0.1127		